Neogenomics Inc: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Jul 30, 2024 and accepted by EDGAR at Jul 30, 2024, 20:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $164.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $320.7m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $92.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $182.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $72.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-01-01 to 2024-06-30 | $138.0m | us-gaap:GrossProfit |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $15.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$21.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$52.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $1.7m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $3.4m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-04-01 to 2024-06-30 | −$375.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | −$995.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$18.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$45.7m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 126,405,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 126,257,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$12.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $18.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $355.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $584.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $1.64bn | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $290.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $727.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | $915.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001077183-24-000109. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.